Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market

Bayer/Algeta’s Xofigo was cleared for castration-resistant prostate cancer patients with symptomatic bone metastases, but uptake of the radiotherapeutic will require referrals from most providers to a licensed radiation site and the company must find a way for the drug to be used instead of or in sequence with chemo and other prostate cancer therapies.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access